BIFIDO Co., Ltd Overview
BIFIDO is a small-cap Korean microbiome company built on human-derived Bifidobacterium strains. The core strains, B. bifidum BGN4 and B. longum BORI, were isolated in 1994 from the guts of Korean infants by founder Professor Ji Geun-eog's research team. Commercially, BIFIDO is mainly a contract (ODM) manufacturer of probiotic health-functional foods: ODM made up 74.6% of FY2025 standalone sales. It also sells branded finished goods (BIFIDOLAB, Zigunuk), almost entirely outside Korea, and bulk strain powders. Its main technical differentiator is regulatory credentialing. BIFIDO describes itself as the first Korean company, and the sixth globally, to hold both US FDA NDI and GRAS status for proprietary strains (BGN4, BORI, AD011). BGN4 is also listed in the US Pharmacopeia. After the 2024 embezzlement crisis, Whan In Pharmaceutical took control. BIFIDO has since retreated from clinical-stage live biotherapeutics, sold its Seoul Microbiome Center for KRW 25.4bn, and refocused on individually-recognised functional ingredients and an early-stage engineered-bifidobacteria (BiGeX/eLBP) platform.
Company's own description (FY2025 business report, paraphrased)
BIFIDO launched its first probiotic finished product in 2001. After Korea's Health Functional Food Act took effect in 2002, it began manufacturing and selling probiotic strain powders ("raw powder", 원말) and health functional foods containing them; the H1 2026 report dates this to March 2004. It runs its own brand BIFIDOLAB, among others, and provides ODM services to domestic and overseas brand owners from a GMP-certified facility. Its proprietary Microbiome Accelerating Platform (MAP) consolidates more than 30 years of gut-microbe isolation, culture and industrialisation know-how. MAP supports functional-probiotic and microbiome-therapeutic development. The company states that its rheumatoid arthritis live-biotherapeutic candidate reached a domestic Phase 1 IND application, but that the application was voluntarily withdrawn in H2 2025 because of legal barriers and insufficient commercial viability. The next-generation programme is BiGeX (Bifidobacterium Gene Expression & Delivery Platform), which aims to create engineered live biotherapeutic products (eLBPs) in which recombinant Bifidobacterium expresses and delivers therapeutic proteins in vivo.
Business model and revenue model
| Revenue stream | Model | FY2025 share of standalone sales (%) | Notes |
|---|---|---|---|
| ODM finished products | Product sales to brand owners (B2B); made-to-specification, high-mix/low-volume | 74.6 | Domestic ODM KRW 12,624m; overseas ODM KRW 1,376m |
| Own-brand finished products | Product sales via overseas local distributors (B2B2C) | 13.1 | Own-brand domestic sales were zero in FY2025 and H1 2026 |
| Raw powder (strain powders) | Ingredient sales to manufacturers (B2B) | 12.3 | Export via local distributors to local manufacturers; domestic direct to manufacturers |
| Merchandise (상품) | Resale of purchased goods (toothpaste, cosmetics, others) | About 4.9 of consolidated revenue (KRW 961m of 19,679m) | Consolidated note 4 |
| Licensing / royalties | Not a reported revenue line | 0 | Pipeline out-licensing is an aspiration (BiGeX), not a current revenue source |
| Subscription / services | — | 0 | — |
All revenue is recognised at a point in time (K-IFRS 1115 note). BIFIDO reports a single operating segment.
Value-chain position
BIFIDO is vertically integrated across strain discovery and isolation, culture and fermentation (35,000-litre fermenter capacity at Hongcheon, per 2018 IPO coverage), freeze-drying, coating and stabilisation (it holds a patented vitamin A/C/E antioxidant coating method, granted Jun 2025), finished-dose manufacturing (stick-pack powders and capsules), and regulatory dossier preparation (GRAS, NDI, Halal, Kosher, China FSMP factory certification). It does not run large-scale domestic B2C retail; brand marketing to Korean consumers is done by its ODM customers. Raw materials are mainly oligosaccharide preparations, sugar preparations, corn starch and packaging film, bought in what the company calls a fully competitive supplier market.
Customer types and end-markets
| Customer type | End-market | Evidence |
|---|---|---|
| Korean health-functional-food brand owners | Domestic probiotic supplements | Domestic ODM KRW 12,624m in FY2025 (67.3% of standalone sales) |
| Overseas distributors (mainly China) | Chinese consumer probiotics via direct-selling / distributor channels | Own-brand exports KRW 2,454m in FY2025; 2024 Chinese direct-selling licence policy change hurt sales |
| Overseas brand owners | Overseas ODM | KRW 1,376m in FY2025 |
| Domestic and overseas food/supplement manufacturers | Ingredient (raw-powder) market, including infant formula use cases supported by GRAS notices | Raw powder KRW 2,304m in FY2025 |
| Pet-food / pet-supplement channel | Companion-animal probiotics (about 33 products launched) | FY2025 report, business objective added 2021 |
Customer concentration. Customer "A" accounted for KRW 5,990m, or 31.93% of FY2025 standalone revenue (KRW 2,160m in FY2024). The three largest finished-product customers (A, B, C) together accounted for 49.3% of FY2025 standalone revenue. In H1 2026, customer A's sales fell to KRW 762m (12.5%) from KRW 3,078m in H1 2025.
Independent characterisation
BIFIDO is economically a sub-scale probiotic ODM and ingredient house: FY2025 consolidated revenue was KRW 19.7bn. It carries a disproportionately large intangible base (strain IP, US regulatory status) and has a history of ambitious but unfunded biotech optionality. Revenue swings with a few ODM customers and with Chinese channel regulation. Despite the "microbiome therapeutics" listing narrative, more than 95% of revenue comes from commodity-like probiotic manufacturing. The 2026 sale of the Gangnam Microbiome Center turned an illiquid real-estate commitment into cash, materially changing the balance-sheet profile against a market capitalisation of about KRW 22bn.
Strategy
Stated strategy (themes paraphrased from the FY2025 business report and H1 2026 report)
-
Strengthen fundamentals first. After withdrawing the RA IND, management says it will prioritise "inner strength", consolidate the competitiveness of the core probiotic business, and pursue innovative therapeutics only over the medium to long term.
-
Move up the value chain in ingredients. Shift from commodity "notified" probiotics, which any manufacturer can produce, to individually-recognised ingredients with an exclusivity period. The company cites a Korean individually-recognised HFF market of about KRW 740.9bn in 2023.
-
Monetise exclusive ingredients through B2B, then B2C. Use existing OEM/ODM channels first; extend to own-brand online B2C after approvals.
-
Premium niches: pet food and supplements, and global infant formula (China infant-strain list registration).
-
China channel diversification: CBEC, multiple distribution partners with evaluation systems, and balanced direct-selling and ODM models.
-
Platform R&D: BiGeX eLBP platform for solid tumours and infections, developed with a government-funded research institute and positioned for co-development and licensing.
Initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| Governance overhaul | Oct 2024 → Mar 2026 | Audit committee, independent directors, 3% rule | Implemented |
| RA programme exit | H2 2025 | Phase 1 IND voluntarily withdrawn; BFD1R01/BFD1R02 suspended | Completed |
| Microbiome Center monetisation | Sep 2025 – Aug 2026 | Held-for-sale classification; KRW 25.4bn sale to Kim YJ Co., Ltd.; stated uses are debt repayment, liquidity, new factory and capacity | Closed 14 Aug 2026 |
| Individually-recognised ingredients | 2025–2027 | Hypersensitive skin (in MFDS review); body fat (filing targeted Aug 2026) | In progress |
| China infant-strain registration | 2026–2029 | Clinical preparation | Early stage |
| BiGeX eLBP platform | Ongoing | BFDe001 (solid tumour), BFDe002 (rCDI) | Discovery / in vitro |
| Strategic financial investment | Aug 2025 | KRW 7.0bn equity-linked bond (FVTPL; fair value KRW 6.4bn at Jun 2026) | Held |
| Parent synergies | From Sep 2024 | Whan In plans links with its health-food distribution subsidiary AsU (애즈유). In 2025 Whan In partly disposed of treasury shares, citing funding for health-functional-food (BIFIDO) and animal-health upgrades | Ongoing; no quantified synergy disclosed |
| Pet probiotics and diagnostics | Ongoing | About 33 pet products; saliva-based diagnostic kit in development | Ongoing |
ESG and sustainability commitments
None disclosed: no emissions targets, sustainability report or ESG policy were identified.
Medium-term financial targets / guidance
Not publicly disclosed. BIFIDO does not publish revenue or margin guidance.
Products & Services
Proprietary probiotic strains (raw-material platform)
| Strain | Origin / deposit | Regulatory status | Claimed / studied functions | Target customer |
|---|---|---|---|---|
| Bifidobacterium bifidum BGN4 | Breast-fed infant faeces; KCCM 80046 | US FDA GRAS GRN 814 (2019); NDI 1079 (2018); USP listing; Halal; Kosher | Immune modulation, diarrhoea, ulcerative colitis, IBS, cognition, mood, acute kidney injury, eczema. Patents cover renal failure, COVID-19, osteoarthritis, anti-rotavirus (with BORI), livestock disease, recombinant anti-inflammatory and anti-cancer (scFv) uses | Supplement and food manufacturers; infant formula |
| Bifidobacterium longum BORI | Breast-fed infant faeces; KCCM 10492 | GRAS GRN 813 (2019); NDI 1082 (2018); Halal; Kosher | Anti-rotavirus (Severance Hospital study), cognition, mood, AKI; COVID-19, osteoarthritis and livestock patents (2025–26) | Same as above |
| Bifidobacterium animalis ssp. lactis AD011 | Breast-fed infant faeces; KCCM 11209 | GRAS GRN 952 (2021, after GRN 875 withdrawal in 2019); NDI 1118 (2019); Halal; Kosher | IBS, eczema; livestock-disease patent (2025) | Same as above |
| B. longum RAPO | KCTC13773BP | Kosher | RA (KR, US, CN patents), cancer prevention, immune balance (with L. plantarum LRC5264), systemic sclerosis / pulmonary fibrosis (patent May 2026) | Former therapeutic candidate; ingredient |
| B. pseudocatenulatum C-RAPO and B. bifidum ATT | KCTC13986BP / KCTC13474BP | Kosher (ATT) | Sjögren's syndrome (KR and two US patents); RA | Research / ingredient |
| L. gasseri HHuMIN-D and L. fermentum / Lacticaseibacillus paracasei OK | Human oral origin | Kosher | Halitosis and dental caries (KR patents 2020, 2024, 2025); halitosis reduction study at Dankook University | Oral-care ingredient (individually-recognised track halted at human-study stage) |
| L. salivarius HHuMin-U | — | Kosher | UTI, vaginitis/vulvitis (patent Jan 2025), anti-norovirus (patent Mar 2026) | Women's health ingredient |
| L. helveticus GUT10 | — | Kosher | UTI (patent 2021) | Ingredient |
| L. sakei RH1117; L. gasseri HHuMin-R | — | — | RA (patents 2021–22) | Research |
| Weissella confusa VP30 | — | Kosher | Constipation (EPS-producing; fermented-milk and jelly product commercialised), skin moisturising (cosmetic patent 2023), skin-barrier essence | Food and cosmetics |
| Lactiplantibacillus plantarum ND88 | — | 2024 SME-ministry support project for FDA GRAS; dental-caries patent (Mar 2025) | Oral health | Ingredient (GRAS pursuit; outcome not disclosed) |
| L. acidophilus AD031; L. casei IBS041 | — | Halal; Kosher | General probiotic | Ingredient |
| Other Kosher-listed strains | B. breve BH12, B. infantis BH07, L. bulgaricus BH047, L. helveticus BH14, L. paracasei CH88, L. plantarum BH02, L. reuteri BH11, L. rhamnosus BH09, L. salivarius BH15, Lactococcus lactis BH10 | Kosher (Orthodox Union) | General probiotic library | Ingredient |
Launch years and pricing for individual strains are not publicly disclosed. Average realised raw-powder export prices were KRW 363,858/kg (FY2023), KRW 401,252/kg (FY2024), KRW 459,966/kg (FY2025) and KRW 477,656/kg (H1 2026). Domestic raw-powder averages are heavily mix-driven: KRW 211,598/kg (FY2023) versus KRW 11,825/kg (FY2025).
Finished products
| Line | Brand(s) | Description | Channel | Launch | Pricing |
|---|---|---|---|---|---|
| Own-brand bifidus supplements | BIFIDOLAB; Zigunuk / 지근억비피더스 (including "Zigunuk Bifidus Premium"; "Family Biome" referenced in 2021 broker coverage) | Bifidus-based probiotic powders and capsules | Exported via local distributors (mainly China); no domestic own-brand sales in FY2025 or H1 2026 | Zigunuk Bifidus 2001 | Average finished-product export price KRW 220.58 per unit (FY2025) |
| ODM probiotics | Customer brands; company references "Bifigen" (비피젠) and others; "Lacfido" (락피도) cited as an ODM product in 2021 broker coverage | Made-to-order probiotic HFFs (stick packs, capsules) | Domestic and overseas brand owners | Ongoing | Average domestic finished-product price KRW 205.07 per unit (FY2025) |
| Pet probiotics | — | About 33 companion-animal probiotic products under the Feed Control Act; saliva-based pathogen diagnostic kit in development | Pet channel | Business objective added Mar 2021 | — |
| Functional foods | — | Constipation-relief fermented-milk jelly (VP30) | — | Productised (date not disclosed) | — |
| Cosmetics and personal care | — | Bifidus-expression and VP30-based cosmetic ingredients (essence, serum; GLP-tested acne and itch claims); merchandise includes toothpaste and cosmetics | B2B / merchandise | — | — |
Development portfolio (ingredients)
| Programme | Functional claim | Status (H1 2026 report) | Target |
|---|---|---|---|
| Hypersensitive-immune skin improvement | Individually-recognised HFF ingredient | Under MFDS review | Approval H1 2027; commercial launch H2 2027 |
| Body-fat reduction | Individually-recognised HFF ingredient (heat-killed / probiotic) | Paper published (by Mar 2026); dossier in final preparation | MFDS filing targeted Aug 2026 (submission not yet confirmed publicly) |
| Halitosis relief | Individually-recognised ingredient | Human study halted; paper published Jun 2025 | Discontinued at human-study stage |
| Cognitive improvement | Individually-recognised ingredient | Human study halted | Discontinued |
| China infant-strain food list registration | Market access for infant products in China | Preparing clinical study | Registration 2028; commercialisation 2029 |
Therapeutics pipeline
| Candidate | Indication | Modality | Status |
|---|---|---|---|
| BFD1R01 | Rheumatoid arthritis | Natural live biotherapeutic | Development suspended. Investigational product made at a GMP CMO; Phase 1 IND filed then voluntarily withdrawn (H2 2025) |
| BFD1R02 | Idiopathic pulmonary fibrosis | Natural live biotherapeutic | Suspended alongside BFD1R01 |
| BFDe001 | Solid tumours | eLBP (immunotoxin-expressing Bifidobacterium) | Expression confirmed; in vitro testing |
| BFDe002 | Recurrent C. difficile infection | eLBP (endolysin-expressing) | Constructing vector and strain |
Financial Narrative
Basis and sources.
-
FY2023–FY2025: DART consolidated statements (FY2025 business report).
-
FY2021–FY2022: S&P Global-normalised data (StockAnalysis), consistent with Butler/Value Line summaries of DART data.
-
Operating income for FY2024 and FY2025 uses DART figures (KRW −4,492m and KRW +1,403m). S&P reports KRW −4,968m and KRW +1,867m because it classifies other operating items differently.
-
FY2025 standalone (parent-only) results were revenue KRW 18,758m, operating income KRW 1,494m and net income KRW +1,158m. Some aggregators quote these instead of consolidated figures (consolidated net income was KRW −193m).
Income statement
Revenue CAGR, FY2021–FY2025: 12.9% a year. The path was highly non-linear: +20%, +28%, −34%, +59%.
Interim update (consolidated, KRW m; H1 2026 semi-annual report):
The H1 2026 net profit is non-operating. It reflects a KRW 3,032m equity-method gain as Ropi Bio's third-party placements lifted its net assets (from KRW −4.2bn to KRW +53.9bn), plus a KRW 688m fair-value gain on the FVTPL bond. Q2 2026 on its own: revenue KRW 3,602m (versus KRW 6,197m), operating loss KRW −410m (versus a profit of KRW +1,339m).
Trend commentary.
-
Revenue. FY2022–FY2023 growth was export-led: FY2023 standalone exports were KRW 9,085m, 53% of sales. The 2024 collapse came from China (exports −56%), compounded by the embezzlement-related trading halt and management distraction. FY2025 recovered on domestic ODM (+67%), concentrated in one customer. H1 2026 reverses most of that gain.
-
Gross margin stays in a 34–40% band when utilisation is normal. It fell to 26.6% in FY2024 on under-absorption, which the CEO's May 2024 letter attributed to lower utilisation as China sales fell.
-
Operating leverage is severe. SG&A including R&D is semi-fixed at about KRW 6–8bn, so a ±KRW 6bn revenue swing moves operating income by about KRW 4–6bn.
-
Below the line, results were repeatedly hit by associate losses (Ropi Bio), CB-related charges in 2023–24 and fair-value moves. FY2021 net income of KRW 4.5bn included a KRW 7.2bn asset-disposal gain (S&P-normalised data; the asset was not identified in the filings reviewed). Reported net income therefore says little about core earnings power.
Balance sheet
Notes:
-
FY2025 working capital includes the KRW 24,844m of held-for-sale real estate. Excluding it, working capital was KRW −1,784m.
-
FY2023 also carried derivative liabilities of KRW 5,376m linked to the CB, which are not included in debt above.
-
At 30 Jun 2026: total assets KRW 64,212m; cash KRW 7,610m; bank debt KRW 10,000m (Woori Bank, 3.94%, maturing 10 Aug 2026, secured on the Daechi-dong property); equity KRW 48,936m; FVTPL bond KRW 6,415m; Ropi Bio KRW 6,268m.
Cash flow
Capex history is dominated by the Gangnam Microbiome Center: land bought April 2021, construction May 2023 to July 2025. FY2021–FY2025 capex totalled KRW 32.3bn. The KRW 25.4bn sale in 2026 recovers most of it in cash. Investing flows in 2023–2025 also included large short-term loans to third parties: KRW 13.0bn in 2023 and KRW 22.35bn in 2024, with KRW 15.0bn collected in 2025. The borrowers were not identified in the sources reviewed.
Ratios
Methodology:
-
ROIC = operating income × (1 − 22% notional tax) ÷ (year-end equity + total debt).
-
FY2025 current ratio is 0.88x excluding held-for-sale assets.
-
Net debt/EBITDA is shown only for net-debt years with positive EBITDA.
-
Working-capital days use year-end balances.
-
S&P TTM metrics (Aug 2026): ROE 4.79%, ROIC 1.86%, Altman Z-score 2.15, Piotroski F-score 6.
Inflections and drivers. Return metrics have never sustainably cleared the cost of capital (S&P estimates WACC at 7.29%). The balance sheet swung from a KRW 21bn net-cash position (FY2021) to net debt (FY2024–FY2025). The causes were real-estate capex, CB redemption, third-party loans and the embezzlement. The August 2026 property sale should restore a net-cash position, subject to confirmation of the Woori Bank loan repayment. The FY2025 cash conversion cycle (96 days) is the best in five years because inventory fell from KRW 2,940m to KRW 1,921m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Own-brand finished products revenue (KRW Mn) | 4,882 | 1,859 | 2,454 |
ODM finished products revenue (KRW Mn) | 10,997 | 8,603 | 14,000 |
Raw powder revenue (KRW Mn) | 1,267 | 1,618 | 2,304 |
Total standalone revenue (KRW Mn) | 17,146 | 12,080 | 18,758 |
Own-brand share of total (%) | 28.5 | 15.4 | 13.1 |
ODM share of total (%) | 64.1 | 71.2 | 74.6 |
Raw powder share of total (%) | 7.4 | 13.4 | 12.3 |
Own-brand YoY growth (%) | — | -61.9 | 32.0 |
ODM YoY growth (%) | — | -21.8 | 62.7 |
Raw powder YoY growth (%) | — | 27.7 | 42.4 |
Total standalone YoY growth (%) | — | -29.5 | 55.3 |
Revenue by Segment
| Metric | FY2024 | FY2025 |
|---|---|---|
Products revenue (KRW Mn) | 11,538 | 18,718 |
Merchandise revenue (KRW Mn) | 812 | 961 |
Total consolidated revenue (KRW Mn) | 12,350 | 19,679 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Category | H1 2026 revenue | Share (%) |
|---|---|---|
Own-brand finished (BIFIDOLAB and others) | 263 | 4.3 |
ODM finished ("Bifigen" and others) | 4,558 | 74.9 |
Raw powder (BGN4 and others) | 1,265 | 20.8 |
Total | 6,086 | 100.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 12,117 | 14,579 | 18,634 | 12,350 | 19,679 |
Revenue growth YoY (%) | -2.1 | 20.3 | 27.8 | -33.7 | 59.3 |
Cost of sales (KRW Mn) | 7,982 | 8,717 | 11,211 | 9,065 | 12,189 |
Gross profit (KRW Mn) | 4,135 | 5,862 | 7,423 | 3,285 | 7,490 |
SG&A incl. R&D (KRW Mn) | 5,152 | 4,599 | 7,767 | 7,776 | 6,087 |
Operating income (KRW Mn) | -1,017 | 1,263 | -344 | -4,492 | 1,403 |
Depreciation & amortisation (KRW Mn) | 1,746 | 1,729 | 1,873 | 1,931 | 1,955 |
EBITDA = operating income + D&A (KRW Mn) | 729 | 2,992 | 1,529 | -2,561 | 3,358 |
Share of associate loss (KRW Mn) | — | — | -1,555 | -1,764 | -1,239 |
Pre-tax income (KRW Mn) | 6,541 | 1,808 | 139 | -6,819 | -484 |
Income tax expense (benefit) (KRW Mn) | 2,048 | 263 | -943 | -1,424 | -291 |
Net income (KRW Mn) | 4,493 | 1,546 | 1,082 | -5,395 | -193 |
EPS basic (KRW) | 551 | 189 | 132 | -660 | -24 |
EPS diluted (KRW) | 551 | 189 | 132 | -660 | -24 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | 34.1 | 40.2 | 39.8 | 26.6 | 38.1 |
Operating margin (%) | -8.4 | 8.7 | -1.8 | -36.4 | 7.1 |
EBITDA margin (%) | 6.0 | 20.5 | 8.2 | -20.7 | 17.1 |
Net margin (%) | 37.1 | 10.6 | 5.8 | -43.7 | -1.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | H1 2025 | H1 2026 | Change (%) |
|---|---|---|---|
Revenue | 11,145 | 6,097 | -45.3 |
Gross profit | 4,653 | 1,749 | -62.4 |
Operating income | 1,418 | -1,007 | n/m |
Share of associate result (Ropi Bio) | -699 | 3,032 | n/m |
Pre-tax income | 1,110 | 2,973 | 167.9 |
Net income | 944 | 2,986 | 216.2 |
Domestic revenue | 6,701 | 4,396 | -34.4 |
Overseas (China etc.) revenue | 4,444 | 1,702 | -61.7 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 54,648 | 54,937 | 71,737 | 61,212 | 61,302 |
Cash and cash equivalents (KRW Mn) | 4,527 | 849 | 5,806 | 1,758 | 7,664 |
Short-term financial instruments (KRW Mn) | 16,489 | 18,464 | 21,502 | 0 | 0 |
Short-term loans receivable, net (KRW Mn) | — | — | — | 14,882 | 350 |
Assets held for sale (KRW Mn) | 0 | 0 | 0 | 0 | 24,844 |
Property, plant and equipment (KRW Mn) | 25,582 | 25,282 | 26,883 | 31,591 | 12,113 |
Goodwill and intangibles (KRW Mn) | 173 | 150 | 113 | 65 | 70 |
Investments in associates (KRW Mn) | — | — | 6,205 | 4,477 | 3,238 |
Short-term bank borrowings (KRW Mn) | 0 | 0 | 0 | 10,700 | 12,000 |
Convertible bonds (KRW Mn) | 0 | 0 | 11,376 | 0 | 0 |
Lease liabilities (KRW Mn) | 215 | 404 | 240 | 265 | 253 |
Total debt (KRW Mn) | 215 | 404 | 11,616 | 10,965 | 12,253 |
Short-term portion of debt (KRW Mn) | 114 | 198 | 11,518 | 10,850 | 12,135 |
Long-term portion of debt (KRW Mn) | 101 | 206 | 98 | 115 | 119 |
Net cash (+) / net debt (−) (KRW Mn) | 20,801 | 18,909 | 15,692 | -9,207 | -4,589 |
Total equity (KRW Mn) | 50,642 | 52,489 | 51,702 | 46,686 | 45,930 |
Working capital (KRW Mn) | 21,631 | 21,960 | 17,762 | 8,468 | 23,060 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | 2,036 | 1,876 | 2,849 | -716 | 3,950 |
Capital expenditure, PP&E (KRW Mn) | -14,633 | -1,049 | -3,292 | -6,108 | -7,194 |
Free cash flow (KRW Mn) | -12,597 | 827 | -443 | -6,824 | -3,244 |
Dividends paid (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Interest paid (KRW Mn) | 10 | 18 | 26 | 178 | 389 |
Net debt issued / (repaid) (KRW Mn) | -119 | -135 | 16,808 | -6,500 | 1,143 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity (%) | 8.9 | 3.0 | 2.1 | -11.0 | -0.4 |
Return on assets (%) | 8.2 | 2.8 | 1.7 | -8.1 | -0.3 |
ROIC (%) | -1.6 | 1.9 | -0.4 | -6.1 | 1.9 |
Current ratio (x) | 6.98 | 12.62 | 1.90 | 1.60 | 2.55 |
Debt to equity (x) | 0.00 | 0.01 | 0.22 | 0.23 | 0.27 |
Net debt to EBITDA (x) | — | — | — | — | 1.37 |
Interest coverage, operating income ÷ interest expense (x) | -106.6 | 69.2 | -1.3 | -6.2 | 3.6 |
Asset turnover (x) | 0.22 | 0.27 | 0.29 | 0.19 | 0.32 |
Days sales outstanding (days) | 39.1 | 47.5 | 57.7 | 50.1 | 48.4 |
Days inventory outstanding (days) | 112.8 | 84.0 | 87.4 | 118.4 | 57.5 |
Days payables outstanding (days) | 16.3 | 6.1 | 20.6 | 18.9 | 9.9 |
Cash conversion cycle (days) | 135.6 | 125.4 | 124.5 | 149.6 | 96.0 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Domestic (Korea) revenue (KRW Mn) | 8,061 | 8,119 | 13,583 |
Overseas (China etc.) revenue (KRW Mn) | 10,573 | 4,231 | 6,096 |
Total consolidated revenue (KRW Mn) | 18,634 | 12,350 | 19,679 |
Domestic share (%) | 43.3 | 65.7 | 69.0 |
Overseas share (%) | 56.7 | 34.3 | 31.0 |
Domestic growth YoY (%) | — | 0.7 | 67.3 |
Overseas growth YoY (%) | — | -60.0 | 44.1 |
Revenue by Region and Revenue by Region (%) — Finished products export
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Finished products export (KRW Mn) | 8,028 | 2,951 | 3,830 |
Finished products domestic (KRW Mn) | 7,851 | 7,511 | 12,624 |
Raw powder export (KRW Mn) | 1,057 | 1,010 | 1,345 |
Raw powder domestic (KRW Mn) | 211 | 609 | 959 |
Total export (KRW Mn) | 9,085 | 3,961 | 5,175 |
Total domestic (KRW Mn) | 8,061 | 8,119 | 13,583 |
Export share of standalone revenue (%) | 53.0 | 32.8 | 27.6 |
Export growth YoY (%) | — | -56.4 | 30.7 |
Share Price History
| Date | Price | Context | Source |
|---|---|---|---|
26 Dec 2018 | 18000 (9000 split-adjusted) | IPO offer price; opened at 36,000 | Biospectator |
18 Jun 2021 | 12,300 | Intraday after US prebiotic patent; market cap about KRW 100.2bn | Aju News |
Sep 2021 | 16,829 | Reference price at Amicogen acquisition (deal implied about 24,490/share) | Dealsite |
22 Mar 2022 | 8,850 | Option grant-date price | FY2025 notes |
23 Mar 2023 | 8,180 | Option grant-date price | FY2025 notes |
27 Mar 2024 | 6,200 | Option grant-date price | FY2025 notes |
30 Aug 2024 | 6,112 | Whan In control-block price (stock suspended) | Smart Today |
16 Jul 2026 | 2,420 | — | StockHub |
11 Aug 2026 | 2,580 | — | Investing.com |
28 Aug 2026 | 2,790 | — | Value Line Korea |
30 Sep 2026 | 2,670 | Latest close retrieved | StockAnalysis |
Change by Horizon
| Horizon | Change | Basis |
|---|---|---|
1-year | −28% to −38% | Aggregator data, Aug–Sep 2026 |
About 3.5-year | −67% | Versus KRW 8,180 in Mar 2023 |
About 5-year | −78% | Versus KRW 12,300 in Jun 2021 |
Since IPO | −70% | Versus split-adjusted KRW 9,000 |
Valuation Multiples
| Multiple | BIFIDO | Basis | Cell Biotech (peer) |
|---|---|---|---|
P/E (x) | 11.8 | TTM net income KRW 1,849m, inflated by the KRW 3.0bn associate gain | 8.52 |
P/B (x) | 0.45 | Equity KRW 48,936m | 1.05 |
P/S (x) | 1.49 | TTM revenue KRW 14,631m | n/v |
EV/Sales (x) | 1.67 | EV KRW 24,449m (Jun-26: market cap + debt KRW 10,218m − cash KRW 7,610m) | n/v |
EV/EBITDA (x) | 34.2 | TTM EBITDA about KRW 714m (DART operating income −1,022 + D&A about 1,736); low-quality denominator | n/v |
Pro forma EV after asset sale (KRW Mn, illustrative) | About 1,600 | Assumes the KRW 22.86bn balance was received and the KRW 10.0bn Woori loan repaid at maturity; excludes the FVTPL bond (KRW 6.4bn) and Ropi Bio stake (KRW 6.3bn) | — |
Share Count (million) and Capital Markets Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Shares outstanding, year-end (million) | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
Share buybacks (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Total debt, year-end (KRW Mn) | 215 | 404 | 11,616 | 10,965 | 12,253 |
Analyst Conclusions
Management guidance and consensus
Guidance: none. Management communicates milestone targets instead of financial guidance: body-fat ingredient filing (Aug 2026 target), hypersensitive-skin approval (H1 2027) with commercial launch (H2 2027), and China infant-strain registration (2028) with commercialisation (2029).
Consensus: no coverage.
Run-rate: on reported trends, FY2026 revenue would be about KRW 12–15bn (H1 2026 KRW 6.1bn; H2 is seasonally stronger per company commentary), with an operating loss unless ODM orders recover. This is an analyst extrapolation, not a forecast.
Bull case
-
Balance-sheet asymmetry. If the Woori loan was repaid from sale proceeds, pro forma cash is about KRW 20bn and bank debt is zero. Adding the FVTPL bond (KRW 6.4bn) and the Ropi Bio stake (KRW 6.3bn book), non-operating assets exceed the KRW 21.8bn market cap, so the core business trades near zero EV. The stock trades at 0.45x book.
-
Demonstrated operating leverage. FY2025 produced KRW 1.4bn operating income and KRW 3.4bn EBITDA on KRW 19.7bn revenue, with a 38% gross margin. A return to FY2025-level volumes, possibly helped by Whan In / AsU channels, restores profitability quickly.
-
Ingredient re-rating optionality. Credentials (GRAS/NDI/USP) plus a near-term individually-recognised approval (H1 2027 target) could move the mix toward exclusive, higher-priced ingredients. Export raw-powder pricing has already risen 31% since FY2023.
Bear case
-
Core business deteriorating. H1 2026 revenue fell 45% and the operating result swung to a KRW 1.0bn loss as customer A's orders dropped 75% and China fell 62%. ODM concentration means visibility is minimal.
-
Capital-allocation and governance discount is earned. The record includes an embezzlement, third-party lending, a written-off equity stake, Level-3 bond investments, and a real-estate project built then sold. Sale proceeds may again go to non-core uses, including the stated "new factory" capex while utilisation is falling.
-
The biotech narrative has collapsed. The RA IND was withdrawn after years of promised clinical entry (targets of 2020, then 2025). The eLBP platform is pre-clinical and faces novel GMO regulation. No sell-side support and a thin, flagged float (May 2026 investment caution) limit any re-rating path.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Mid-Nov 2026 | Q3 2026 report: confirmation of loan repayment, use of KRW 22.86bn proceeds, Q3 revenue trend (customer A, China) |
| Q4 2026 | Confirmation of MFDS filing for the body-fat ingredient (Aug 2026 target) |
| Q4 2026 – Q1 2027 | Any announcement on the Hongcheon new-factory capex scope and budget |
| Ongoing | Ropi Bio financing and pipeline (drives equity-method results and impairment risk) |
| Ongoing | FVTPL bond conversion, redemption or fair-value changes |
| Mar 2027 | FY2026 business report and AGM (dividend or capital-return policy, board changes) |
| H1 2027 | MFDS decision on the hypersensitive-skin ingredient |
| Ongoing | Whan In actions: stake changes, intra-group distribution deals, possible tender or merger |
Analyst verdict
BIFIDO is no longer the "Korean microbiome pioneer" its 2018 IPO advertised. It is now a sub-scale probiotic ODM and ingredient manufacturer, with genuinely valuable regulatory and IP assets attached to a history of poor capital stewardship.
The investment debate has narrowed to two questions. Will the controlling shareholder deploy the newly freed cash productively? And can the ingredient strategy reduce dependence on a few ODM customers and on Chinese channel policy?
On the first question, the August 2026 property sale is the most important event since the Whan In takeover. If, as appears likely though unconfirmed, the KRW 10bn secured loan was retired, BIFIDO holds net cash of about KRW 20bn plus about KRW 12.7bn of book-value financial and associate assets. Together these exceed its market capitalisation, and the stock trades at under half of book value. That provides a meaningful valuation floor, though not a catalyst, because minority shareholders cannot compel distributions and the company has never paid a dividend.
On the second question, the evidence is mixed at best. FY2025 showed the plant can earn high-single-digit operating margins at about KRW 20bn of revenue. H1 2026 showed how quickly one customer and one market can remove half of revenue. The individually-recognised ingredient programme is the right strategic answer, but approvals are 2027 events at the earliest, and the company has a record of slipping timelines. The eLBP platform should be valued at close to zero until partnered.
Governance has improved formally, with an audit committee, independent directors and the 3% rule. However, both co-CEOs are insiders, one of whom runs the parent, and minority protection rests largely on Whan In's intentions.
Net assessment: a deep-value, low-quality special situation. The downside is cushioned by cash and the upside depends on capital allocation and execution; there is no earnings momentum. Close monitoring of the Q3 2026 disclosure on use of proceeds is warranted before any constructive stance.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed / tenure | Background (as disclosed or reported) |
|---|---|---|---|
Lee Won-beom (이원범) | Co-CEO and inside director | Director and CEO since 15 Oct 2024 | CEO of Whan In Pharmaceutical (largest shareholder); second-generation owner, son of Whan In chairman Lee Kwang-sik; holds 3.27% of Whan In (Dealsite) |
Park Myeong-su (박명수) | Co-CEO and inside director | Inside director since Mar 2022; CEO since 2 Mar 2023 | Long-time BIFIDO executive. Chaired the June 2024 KMB bifidobacteria symposium; bought BIFIDO shares personally in June 2024 |
Cho Ju-yeon (조주연) | Outside (independent) director; audit committee | Since 15 Oct 2024 | — |
Lee Dong-su (이동수) | Outside (independent) director; audit committee | Since 15 Oct 2024 | — |
Cho Han-ju (조한주) | Outside (independent) director; audit committee | Since 15 Oct 2024 | — |
Baek Su-ok (백수옥) | Head of Management Division (reporting officer) | — | Signs DART filings as preparer |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
14 Sep 2021 | Founder Ji Geun-eog resigns as director; Shin Yong-cheol, Park Chan-ju, Lee Sang-hee (inside) and Kim Mi-ri (outside) join | Amicogen takeover |
22 Mar 2022 | Kwon Bin and Park Myeong-su join as inside directors; Park Seong-hwan as outside director | — |
31 Aug 2022 | Kwon Bin resigns as director | — |
2 Mar 2023 | Park Myeong-su becomes CEO (co-CEO with Shin Yong-cheol) | — |
23 Mar 2023 | Han Nok-yeop joins as outside director | — |
21 Sep 2023 | Kim Byung-hwan appointed statutory auditor (replacing Sung Jin-hyuk) | — |
27 Mar 2024 | Shin Ji-hye joins; Shin Yong-cheol, Lee Sang-hee and Kim Mi-ri re-appointed; Park Chan-ju leaves | — |
15 Oct 2024 | Lee Won-beom becomes co-CEO; Shin Yong-cheol, Lee Sang-hee, Shin Ji-hye, Kim Mi-ri, Han Nok-yeop and auditor Kim Byung-hwan leave; three new outside directors | Whan In takeover after the embezzlement; Amicogen-era management exits |
Major Shareholders
| Holder | Shares | Stake (%) | Date |
|---|---|---|---|
Whan In Pharmaceutical Co., Ltd. | 2,454,000 | 30.00 | 30 Jun 2026 |
Ji Geun-eog (founder) | 428,842 | 5.24 | 30 Jun 2026 (424,436; 5.19% at FY2025 year-end) |
Kwon Bin (former director / vice president) | 296,512 | 3.62 | 30 Jun 2026 |
Officers (aggregate) | 90,113 | 1.10 | 30 Jun 2026 |
Other shareholders | 4,910,533 | 60.04 | 30 Jun 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning versus BIFIDO |
|---|---|---|---|
Korean probiotic brands, ingredients and exports | Cell Biotech (쎌바이오텍, KOSDAQ 049960; "Duolac") | Listed probiotic specialist | About 2.7x BIFIDO's revenue; 11 strains with FDA GRAS (it claims the world's most); 55 export countries; consistently profitable; pays dividends |
Korean probiotic ingredients | Medyogen (메디오젠) | Private strain/ingredient maker | — |
Korean HFF ODM | Kolmar BNH (KOSDAQ) | Large HFF ODM | — |
Korean HFF ODM | Cosmax NBT | HFF ODM | — |
Korean HFF ODM | Novarex (KOSDAQ) | HFF ODM with individually-recognised ingredient portfolio | — |
Korean consumer probiotics | hy (formerly Korea Yakult) | Dairy and probiotic brand | — |
Korean consumer probiotics | Chong Kun Dang Health ("Lacto-fit") | Consumer HFF brand | — |
Korean consumer HFF | GC Wellbeing (녹십자웰빙) | Named by THE VC as a peer | — |
Global probiotic ingredients | Novonesis (Chr. Hansen), IFF (Danisco), Morinaga Milk (BB536), Probi AB, Lallemand, Kaneka Probiotics | Multinational strain suppliers | Orders of magnitude larger; set global price and quality benchmarks; compete for GRAS-grade infant and supplement strains |
Microbiome therapeutics (Korea) | KoBioLabs, Genome & Company, CJ Bioscience, BioMe (Celltrion-backed) | LBP developers | BIFIDO has exited the clinical LBP race; BiGeX is pre-clinical |
Peer Comparison FY2025
| Metric | BIFIDO | Cell Biotech | Kolmar BNH | Novarex |
|---|---|---|---|---|
Revenue FY2025 (KRW Bn) | 19.7 | 53.1 | n/v | n/v |
Revenue growth FY2025 (%) | 59.3 | 6.4 | n/v | n/v |
Operating income FY2025 (KRW Bn) | 1.4 | 7.9 | n/v | n/v |
Operating margin FY2025 (%) | 7.1 | 14.9 | n/v | n/v |
Net income FY2025 (KRW Bn) | -0.2 | 10.1 | n/v | n/v |
R&D intensity (%) | 8.2 (S&P basis) / 11.5 (company gross) | n/v | n/v | n/v |
P/E (x) | 11.8 (TTM Jun-26) | 8.52 | n/v | n/v |
P/B (x) | 0.45 | 1.05 | n/v | n/v |
Dividend yield (%) | 0 | 3.94 | n/v | n/v |
Market cap (KRW Bn) | 21.8 | 143.2 | n/v | n/v |
Peer Comparison FY2025 (Annual)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
BIFIDO revenue (KRW Bn) | 12.1 | 14.6 | 18.6 | 12.4 | 19.7 |
Cell Biotech revenue (KRW Bn) | 46.9 | 50.5 | 53.8 | 49.9 | 53.1 |
BIFIDO operating income (KRW Bn) | -1.0 | 1.3 | -0.3 | -4.5 | 1.4 |
Cell Biotech operating income (KRW Bn) | 7.3 | 6.1 | 2.2 | 6.8 | 7.9 |



